克拉斯
表皮生长因子受体
腺癌
癌症研究
突变
错义突变
癌症
生物
癌
医学
肿瘤科
内科学
结直肠癌
基因
遗传学
作者
Zhimin Liu,Lina Liu,Mei Li,Zhaohui Wang,Lu Feng,Qiuping Zhang,Shihua Cheng,Shenzhou Lu
出处
期刊:Pathology
[Elsevier]
日期:2011-04-01
卷期号:43 (3): 234-238
被引量:27
标识
DOI:10.1097/pat.0b013e328344e61b
摘要
Epidermal growth factor receptor (EGFR) and Kirsten-RAS (KRAS) mutations have been identified as predictors of response to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer. We aimed to screen the mutations of both genes in gastric carcinoma to detect the suitability of EGFR TKIs for patients with gastric carcinoma.We screened EGFR mutation in exons 19-21 and KRAS mutation in exon 2 in 58 gastric adenocarcinomas from China using high resolution melting analysis (HRMA). Positive samples were confirmed by DNA sequencing.Three EGFR missense mutations (5.2%) and 22 single nucleotide polymorphisms (SNP, Q787Q, 37.9%) were identified. To our knowledge, we report for the first time three mutation patterns of EGFR, Y801C, L858R and G863D, in gastric carcinoma. Two samples with EGFR mutation were mucinous adenocarcinoma. These three samples were collected from male patients aged over 75 years old. The frequency of KRAS mutation was 10.3% (6/58). The exclusiveness of EGFR and KRAS mutations was proven for the first time in gastric cancer.Gastric carcinoma of the mucinous adenocarcinoma type collected from older male patients may harbour EGFR mutations. The small subset of gastric adenocarcinoma patients may respond to EGFR TKIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI